Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study

Autor: José Federico González González, Jaime Feliu, P. Vicente, Esther Casado Gonzalez, Guillermo Lopez-Vivanco, Ana Montes, Carmen Garcia Piernavieja, Teresa Macarulla, Irene Gonzalez Cebrian, A. Muñoz, Manuel Valladares-Ayerbes, Mónica Jorge Fernández, Juan Ignacio Delgado-Mingorance, Bartomeu Massuti, Ana Albero, Rebeca Mondéjar Solís, Guillermo Quintero-Aldana

Publikováno v: CANCER CHEMOTHERAPY AND PHARMACOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Digital.CSIC. Repositorio Institucional del CSIC

[Purpose] To evaluate the health-related quality of life (HRQoL), global health status (GHS), and deterioration-free survival of an elderly population (> 70 years) with unresectable locally advanced (LAPC) or metastatic pancreatic cancer (mPC) treate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a672bc10eeb5fd2ed44a11fb2bed1c7c
https://pubmed.ncbi.nlm.nih.gov/33452559